Výsledky vyhledávání - "Clementino, NCD"

Akademický článek

Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.

Autor: Hughes TP; South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, SA, Australia. tim.hughes@sahmri.com., Clementino NCD; Hospital Das Clinicas Da UFMG, Belo Horizonte, Brazil., Fominykh M; Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation.; Saint Petersburg State University, Saint Petersburg, Russian Federation., Lipton JH; Princess Margaret Cancer Centre, Toronto, ON, Canada., Turkina AG; National Research Center for Hematology, Moscow, Russian Federation., Moiraghi EB; Hospital General De Agudos J. M. Ramos Mejia, Buenos Aires, Argentina., Nicolini FE; Hematology Department, Centre Léon Berard, Lyon, France., Takahashi N; Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan., Sacha T; Department of Hematology, Jagiellonian University Hospital, Krakow, Poland., Kim DW; Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea., Fellague-Chebra R; Novartis Pharma SAS, Rueil-Malmaison, Paris, France., Tiwari R; Novartis Healthcare Pvt. Ltd, Hyderabad, India., Bouard C; Novartis Pharma SAS, Rueil-Malmaison, Paris, France., Mahon FX; Cancer Center of Bordeaux, Institut Bergonié, INSERM U1218, University of Bordeaux, Bordeaux, France.

Publikováno v: Leukemia [Leukemia] 2021 Jun; Vol. 35 (6), pp. 1631-1642. Date of Electronic Publication: 2021 May 12.

Zobrazit plný text záznamu

Akademický článek

Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular: Project guidelines: Associação Médica Brasileira - 2019.

Autor: Tavares RS; Universidade Federal de Goiás (UFG), Goiania, GO, Brazil. Electronic address: renatosampaiotavares@gmail.com., Nonino A; Instituto Hospital de Base do Distrito Federal (IHBDF), Brasília, DF, Brazil., Pagnano KBB; Universidade Estadual de Campinas (Unicamp), Campinas, SP, Brazil., Nascimento ACKVD; Irmandade da Santa Casa de Misericórdia de São Paulo, São Paulo, SP, Brazil., Conchon M; Hospital Santa Marcelina, São Paulo, SP, Brazil., Fogliatto LM; Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil., Funke VAM; Universidade Federal do Paraná, (UFPR), Curitiba, PR, Brazil., Bendit I; Hospital Das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil., Clementino NCD; Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil., Chauffaille MLLF; Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brazil., Bernardo WM; Hospital Das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), São Paulo, SP, Brazil; Associação Médica Brasileira (AMB), São Paulo, SP, Brazil., Santos FPS; Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.

Publikováno v: Hematology, transfusion and cell therapy [Hematol Transfus Cell Ther] 2019 Jul; Vol. 41 Suppl 1, pp. 1-73. Date of Electronic Publication: 2019 May 10.

Zobrazit plný text záznamu

Akademický článek

Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.

Autor: Mahon FX; University of Bordeaux, Bordeaux, France (F.M.)., Boquimpani C; Hemocentro do Rio de Janeiro, HEMORIO, Rio de Janeiro, Brazil (C.B.)., Kim DW; The Catholic University of Korea, Seoul, South Korea (D.K.)., Benyamini N; Rambam Health Care Campus, Haifa, Israel (N.B.)., Clementino NCD; Hospital Das Clinicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil (N.C.C.)., Shuvaev V; Russian Research Institute of Hematology and Transfusiology, Saint Petersburg, Russia (V.S.)., Ailawadhi S; Mayo Clinic, Jacksonville, Florida (S.A.)., Lipton JH; University of Toronto, Toronto, Ontario, Canada (J.H.L.)., Turkina AG; National Research Center for Hematology, Moscow, Russia (A.G.T.)., De Paz R; University Hospital La Paz, Madrid, Spain (R.D.)., Moiraghi B; Hospital General De Agudos J. M. Ramos Mejia, Buenos Aires, Argentina (B.M.)., Nicolini FE; Centre Hospitalier Lyon Sud, Pierre-Bénite, France (F.E.N.)., Dengler J; Onkologische Praxis Heilbronn, Heilbronn, Germany (J.D.)., Sacha T; Jagiellonian University Hospital, Kraków, Poland (T.S.)., Takahashi N; Akita University Hospital, Akita, Japan (N.T.)., Fellague-Chebra R; Novartis Pharma SAS, Rueil-Malmaison, France (R.F.)., Acharya S; Novartis Healthcare Pvt Ltd, Hyderabad, India (S.A.)., Wong S; Novartis Oncology Precision Medicine, Cambridge, Massachusetts (S.W.)., Jin Y; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey (Y.J.)., Hughes TP; University of Adelaide, Adelaide, South Australia, Australia (T.P.H.).

Publikováno v: Annals of internal medicine [Ann Intern Med] 2018 Apr 03; Vol. 168 (7), pp. 461-470. Date of Electronic Publication: 2018 Feb 20.

Zobrazit plný text záznamu

Akademický článek

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results.

Autor: Hughes TP; Division of Haematology, SA Pathology and South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, South Australia, Australia., Leber B; Clinical Pathology, McMaster University, Hamilton, Ontario, Canada., Cervantes F; Department of Hematology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain., Spector N; Departamento de Clínica Médica/FM, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil., Pasquini R; Division of Hematology and Medical Oncology, Federal University of Paraná, Curitiba, Brazil., Clementino NCD; Hospital Das Clinicas da UFMG, Belo Horizonte, Brazil., Schwarer AP; Department of Hematology, Alfred Hospital, Melbourne, Victoria, Australia., Dorlhiac-Llacer PE; Department of Hematology, Hospital das Clinicas FMUSP, São Paulo, Brazil., Mahon FX; Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, Inserm U1035, Université Victor Ségalen, Bordeaux, France., Rea D; Unité de Thérapie Cellulaire et Clinique Transfusionnelle, Service des Maladies du Sang et EA3518, Hôpital Saint-Louis, Paris, France., Guerci-Bresler A; Department of Hematology, Brabois Hospital, Vandoeuvre-lès-Nancy, Vandoeuvre, France., Kamel-Reid S; Clinical Laboratory Genetics, Genome Diagnostics, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada., Bendit I; Hematology Unit, Faculty of Medicine, University of São Paulo, São Paulo, Brazil., Acharya S; Novartis Healthcare Pvt Ltd, Hyderabad, India., Glynos T; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Dalal D; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Branford S; Leukaemia Unit, Centre for Cancer Biology, SA Pathology, University of South Australia and University of Adelaide, Adelaide, South Australia, Australia., Lipton JH; Blood and Marrow Transplant Service, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.

Publikováno v: Leukemia [Leukemia] 2017 Nov; Vol. 31 (11), pp. 2529-2531. Date of Electronic Publication: 2017 Aug 03.

Zobrazit plný text záznamu

Akademický článek

Imatinib treatment duration is related to decreased estimated glomerular filtration rate in chronic myeloid leukemia patients.

Autor: Marcolino MS; School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. Electronic address: milenamarc@gmail.com., Boersma E; Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands., Clementino NCD; School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Hematology Service, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Macedo AV; School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Hematology Service, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Marx-Neto AD; School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., Silva MHCR; School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil., van Gelder T; Departments of Internal Medicine; Hospital Pharmacy, Erasmus MC, Rotterdam, The Netherlands., Akkerhuis KM; Department of Cardiology, Erasmus MC, Rotterdam, The Netherlands., Ribeiro AL; School of Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil; Cardiology Service, Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2011 Sep; Vol. 22 (9), pp. 2073-2079. Date of Electronic Publication: 2011 Feb 10.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání